CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Improvement in Glucose Regulation Using a Digital Tracker and Continuous Glucose Monitoring in Healthy Adults and Those with Type 2 Diabetes

Open access

Abstract

INTRODUCTION: While continuous glucose monitoring (CGM) has been shown to decrease both hyper- and hypoglycemia in insulin-treated diabetes, its value in non-insulin-treated type 2 diabetes (T2D) and prediabetes is unclear. Studies examining the reduction in hyperglycemia with the use of CGM in non-insulin-treated T2D are limited. METHODS: We investigated the potential benefit of CGM combined with a mobile app that links each individual's glucose tracing to meal composition, heart rate, and physical activity in a cohort of 1022 individuals, ranging from nondiabetic to non-insulin-treated T2D, spanning a wide range of demographic, geographic, and socioeconomic characteristics. The primary endpoint was the change in time in range (TIR), defined as 54-140 mg/dL for healthy and prediabetes, and 54-180 mg/dL for T2D, from the beginning to end of a 10-day period of use of the Freestyle Libre CGM. Logged food intake, physical activity, continuous glucose, and heart rate data were captured by a smartphone-based app that continuously provided feedback to participants, overlaying daily glucose patterns with activity and food intake, including macronutrient breakdown, glycemic load (GL), and glycemic index (GI). RESULTS: A total of 665 participants meeting eligibility and data requirements were included in the final analysis. Among self-reported nondiabetic participants, CGM identified glucose excursions in the diabetic range among 15% of healthy and 36% of those with prediabetes. In the group as a whole, TIR improved significantly (p < 0.001). Among the 51.4% of participants who improved, TIR increased by an average of 6.4% (p < 0.001). Of those with poor baseline TIR, defined as TIR below comparable A1c thresholds for T2D and prediabetes, 58.3% of T2D and 91.7% of healthy/prediabetes participants improved their TIR by an average of 22.7% and 23.2%, respectively. Predictors of improved response included no prior diagnosis of T2D and lower BMI. CONCLUSIONS: These results indicate that 10-day use of CGM as a part of multimodal data collection, with synthesis and feedback to participants provided by a mobile health app, can significantly reduce hyperglycemia in non-insulin-treated individuals, including those with early stages of glucose dysregulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-021-01081-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design, Sugar AI app, and subject selection. a Ten-day study design to evaluate improvement in time in range (TIR) as a result of continuous glucose monitoring (CGM) and a mobile app (Sugar AI) that integrates glucose curves with eating and physical activity patterns in healthy nondiabetics and those with prediabetes or non-insulin-treated type 2 diabetes. b Snapshot of the Sugar AI app designed for this trial. Users visualize their concurrent food and activity logs on top of their CGM and heart rate signals. c Diagram showing the number of participants recruited and the number of participants that were included in this study
Fig. 1 Study design, Sugar AI app, and subject selection. a Ten-day study design to evaluate improvement in time in range (TIR) as a result of continuous glucose monitoring (CGM) and a mobile app (Sugar AI) that integrates glucose curves with eating and physical activity patterns in healthy nondiabetics and those with prediabetes or non-insulin-treated type 2 diabetes. b Snapshot of the Sugar AI app designed for this trial. Users visualize their concurrent food and activity logs on top of their CGM and heart rate signals. c Diagram showing the number of participants recruited and the number of participants that were included in this studyCC BY-NC · PubMed Central
Fig. 2 Frequency of glucose dysregulation in self-claimed healthy participants. a Classification as healthy, prediabetes, and type 2 diabetes based on continuous glucose monitor values (vertical axis) in each self-claimed classification group (horizontal axis). b Variability in glucose responses to a 45-g oral glucose drink administered after an overnight fast in two healthy participants. c Heatmap showing the fraction of time individuals (shown in rows) spent in each of the glycemic signature classes, or “glucotype” (low, moderate, and high glucose values) as defined by Hall et al. [32]. The heat map intensity indicates the fraction of time individuals spent in each glycemic signature class with 1 being 100% of the time. Rows of individuals are arranged according to hierarchical clustering. All participants (n = 665) were used to create the heatmap and the left column “classification” shows the self-claimed classification group. d Heatmap showing the fraction of time T2D participants spent in each of the glycemic classes. The column on the left shows the T2Ds according to medication use
Fig. 2 Frequency of glucose dysregulation in self-claimed healthy participants. a Classification as healthy, prediabetes, and type 2 diabetes based on continuous glucose monitor values (vertical axis) in each self-claimed classification group (horizontal axis). b Variability in glucose responses to a 45-g oral glucose drink administered after an overnight fast in two healthy participants. c Heatmap showing the fraction of time individuals (shown in rows) spent in each of the glycemic signature classes, or “glucotype” (low, moderate, and high glucose values) as defined by Hall et al. [32]. The heat map intensity indicates the fraction of time individuals spent in each glycemic signature class with 1 being 100% of the time. Rows of individuals are arranged according to hierarchical clustering. All participants (n = 665) were used to create the heatmap and the left column “classification” shows the self-claimed classification group. d Heatmap showing the fraction of time T2D participants spent in each of the glycemic classes. The column on the left shows the T2Ds according to medication useCC BY-NC · PubMed Central
Fig. 3 Time in range (TIR) improvement across all cohorts. a Histogram of number of participants within each TIR bin over the first 2 days (days 2–3: day 1 excluded for potential CGM inaccuracy) compared to TIR over the last 2 days (days 8–9: (day 10 excluded for potential CGM inaccuracy) of the Sugar Challenge Study. TIR improved significantly overall. b An example of the first 2 days (top panel) compared to the last 2 days (bottom panel) of CGM data of a T2D participant on metformin. c Histogram of T2D participants within each TIR bin over days 2–3 compared to TIR over days 8–9 of the Sugar Challenge Study, showing significant improvement. d Histogram of healthy/prediabetes participants within each TIR bin over days 2–3 compared to TIR over days 8–9 of the Sugar Challenge Study, showing significant improvement
Fig. 3 Time in range (TIR) improvement across all cohorts. a Histogram of number of participants within each TIR bin over the first 2 days (days 2–3: day 1 excluded for potential CGM inaccuracy) compared to TIR over the last 2 days (days 8–9: (day 10 excluded for potential CGM inaccuracy) of the Sugar Challenge Study. TIR improved significantly overall. b An example of the first 2 days (top panel) compared to the last 2 days (bottom panel) of CGM data of a T2D participant on metformin. c Histogram of T2D participants within each TIR bin over days 2–3 compared to TIR over days 8–9 of the Sugar Challenge Study, showing significant improvement. d Histogram of healthy/prediabetes participants within each TIR bin over days 2–3 compared to TIR over days 8–9 of the Sugar Challenge Study, showing significant improvementCC BY-NC · PubMed Central
Fig. 4 The group with poor time in range (TIR) at baseline. a Percentage of users within each cohort with TIR improvement. b Percentage of users within each cohort for whom the 8-day improvement exceeded the daily TIR variation. c Comparison of days 2–3 and days 8–9 TIR for participants who started below 72% (6.5% HbA1c equivalent for T2D users) and below 83% (5.7% HbA1c equivalent/Healthy users) at baseline. d Comparison of days 2–3 and days 8–9 TIR for T2D participants who started below 72% at baseline. e Comparison of days 2–3 and days 8–9 TIR for healthy/prediabetes participants who started below 83% at baseline. f Histogram of TIR improvement over T2D participants who started below 72% and healthy participants who started below 83% at baseline
Fig. 4 The group with poor time in range (TIR) at baseline. a Percentage of users within each cohort with TIR improvement. b Percentage of users within each cohort for whom the 8-day improvement exceeded the daily TIR variation. c Comparison of days 2–3 and days 8–9 TIR for participants who started below 72% (6.5% HbA1c equivalent for T2D users) and below 83% (5.7% HbA1c equivalent/Healthy users) at baseline. d Comparison of days 2–3 and days 8–9 TIR for T2D participants who started below 72% at baseline. e Comparison of days 2–3 and days 8–9 TIR for healthy/prediabetes participants who started below 83% at baseline. f Histogram of TIR improvement over T2D participants who started below 72% and healthy participants who started below 83% at baselineCC BY-NC · PubMed Central
Fig. 5 TIR responders vs non-responders. a All participant probability density function (PDF) of TIR change for good responders vs poor responders b T2D participant probability density function (PDF) of TIR change for good responders vs poor responders. c Healthy/prediabetes participant probability density function (PDF) of TIR change for good responders vs poor responders. d (All participants) Poor responders are older than good responders. e (Healthy participants) Poor responders are older than good responders. f (All participants) Poor responders have higher BMI than good responders. g (Healthy/prediabetes participants) Poor responders have higher BMI than good responders
Fig. 5 TIR responders vs non-responders. a All participant probability density function (PDF) of TIR change for good responders vs poor responders b T2D participant probability density function (PDF) of TIR change for good responders vs poor responders. c Healthy/prediabetes participant probability density function (PDF) of TIR change for good responders vs poor responders. d (All participants) Poor responders are older than good responders. e (Healthy participants) Poor responders are older than good responders. f (All participants) Poor responders have higher BMI than good responders. g (Healthy/prediabetes participants) Poor responders have higher BMI than good respondersCC BY-NC · PubMed Central
Fig. 6 Effect of standardized meals. a Percentage of participants within each cohort who spike (i.e., CGM > 200 mg/dL) after consuming glucose shot, Kind bar, and Garden of Life high-protein Bar. b Correlation between each participant spike to Kind bar (horizontal axis) and their spike to Garden of Life bar (vertical axis) (Pearson correlation) where marker size indicates their spike to a 45-g glucose drink across healthy, prediabetes, T2D on metformin, T2D on no antidiabetic medication, and T2D on multiple medications. c Percentage of participants within each medication cohort of T2D population who spike (i.e., CGM > 200 mg/dL) after consuming glucose drink (45 g), Kind bar, and Garden of Life bar. d Correlation between each participant spike to a 45-g glucose drink (horizontal axis) and their spike to Garden of Life bar (vertical axis) (Pearson correlation) where marker size indicates their response to Kind bar across healthy, prediabetes, T2D on metformin, T2D on no antidiabetic medication, and T2D on multiple medications
Fig. 6 Effect of standardized meals. a Percentage of participants within each cohort who spike (i.e., CGM > 200 mg/dL) after consuming glucose shot, Kind bar, and Garden of Life high-protein Bar. b Correlation between each participant spike to Kind bar (horizontal axis) and their spike to Garden of Life bar (vertical axis) (Pearson correlation) where marker size indicates their spike to a 45-g glucose drink across healthy, prediabetes, T2D on metformin, T2D on no antidiabetic medication, and T2D on multiple medications. c Percentage of participants within each medication cohort of T2D population who spike (i.e., CGM > 200 mg/dL) after consuming glucose drink (45 g), Kind bar, and Garden of Life bar. d Correlation between each participant spike to a 45-g glucose drink (horizontal axis) and their spike to Garden of Life bar (vertical axis) (Pearson correlation) where marker size indicates their response to Kind bar across healthy, prediabetes, T2D on metformin, T2D on no antidiabetic medication, and T2D on multiple medicationsCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 62

Metadata

Authors
Dehghani Zahedani, A., Shariat Torbaghan, S., Rahili, S., Karlin, K., Scilley, D., Thakkar, R., Saberi, M., Hashemi, N., Perelman, D., Aghaeepour, N., McLaughlin, T., & Snyder, M. P.
Corresponding author
Snyder, Michael P.
Venue
Diabetes Therapy
Published
2021-05-28
Volume
12
Issue
7
Pages
1871-1886
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3164167890
Cited by
62
References
32
Citations by year
2026: 11 · 2025: 22 · 2024: 9 · 2023: 15 · 2022: 5
FWCI
5.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
January, Inc.
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
continuous glucose monitoring, type 2 diabetes, prediabetes, glucose regulation, hyperglycemia, time in range, mobile health apps, digital health, glycemic load, glycemic index, macronutrient intake, physical activity, heart rate, FreeStyle Libre, non-insulin-treated diabetes, glycemic excursions, body mass index, predictors of treatment response, healthy adults

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improvement in Glucose Regulation Using a Digital Tracker and Continuous Glucose Monitoring in Healthy Adults and Those with Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s13300-021-01081-3
The paper
Dehghani Zahedani, A., Shariat Torbaghan, S., Rahili, S., Karlin, K., Scilley, D., Thakkar, R., Saberi, M., Hashemi, N., Perelman, D., Aghaeepour, N., McLaughlin, T., & Snyder, M. P. (2021). Improvement in Glucose Regulation Using a Digital Tracker and Continuous Glucose Monitoring in Healthy Adults and Those with Type 2 Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-021-01081-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.